Adaptimmune and TCR2 Tx Complete Strategic Combination
On Thursday, June 1, Adaptimmune announced (press release) the completion of the strategic combination with TCR2 to form a preeminent cell therapy company to treat solid tumors. Moreover, the company hosted an event to elaborate on the newly established clinical milestones for all the assets in its pipeline (webcast / presentation) Below, Celltelligence provides insights on the approval of the merger by the companies’ shareholders, while discussing the future of its combined pipeline.